Page 13 - Covid_NL_11_9_21

In the current deployment, the ship has delivered COVID-19 relief material to Indonesia, Vietnam prior to arriving in Thailand.
Website link:
https://pib.gov.in/PressReleseDetailm.aspx?PRID=1751779
DBT’s ‘Mission COVID Suraksha’ supported Biological E Limited’s novel COVID-19 vaccine candidate, CORBEVAX receives DCGI approval for two clinical trials
DBT has taken myriads of initiatives to increase investments in research and development (R&D) and manufacturing of COVID-19 vaccines. ‘Mission COVID Suraksha’ is one such endeavour for COVID-19 vaccine development to reinforce and streamline available resources towards accelerated vaccine development, to bring in safe, efficacious, affordable and accessible COVID-19 vaccine for the citizens at the earliest under the aegis of Atmanirbhar Bharat.
The DBT and its PSU, Biotechnology Industry Research Assistance Council (BIRAC) have supported Biological E’s COVID-19 vaccine candidate from the pre-clinical stage to phase III clinical studies. In addition to receiving financial assistance under ‘Mission COVID Suraksha’, this vaccine candidate has also obtained financial support under COVID-19 research consortia through National Biopharma Mission, BIRAC.
Biological E. has received DCGI approval for conducting phase III comparator safety and immunogenicity trial in adults after Subject Expert Committee’s (SEC) review of phase I and II clinical trials data. Additionally, Biological E. also received approval on 1 September 2021 to initiate phase II/III study to evaluate safety, reactogenicity, tolerability and immunogenicity of CORBEVAXTM vaccine in children and adolescents. The candidate is a RBD protein sub-unit vaccine.
Website link:
https://pib.gov.in/PressReleseDetailm.aspx?PRID=1751664
ICMR invites expression of interest for validation of rapid antigen
detection assays for COVID-19
ICMR invites applications for validation of rapid antigen detection tests for COVID-19 from all manufacturers who have developed rapid antigen test (RAT) kits. Requirements for validations are based on various categories, like first-time validation, revalidation, and validation with alternate sample types. The gold standard RT-PCR diagnostic test for COVID-19 has limitations in terms of widespread availability. In view of this, there is urgent requirement for reliable and convenient rapid point of care antigen detection assays with high sensitivity and specificity. Such assays could be used as potential diagnostic tests in all possible public and private health care settings and made available for mass testing.
Deadline: Open till next announcement
Contact info:
guptanivedita.hq@icmr.gov.in, drneetu.vijay@icmr.gov.in
Website link:
https://www.icmr.gov.in/pdf/tender/Revised_EOI_for_Ag_kit_ validation_13082021.pdf
VOL. IV ISSUE 10
VIGYAN PRASAR 9
COVID-19 SCIENCE & TECHNOLOGY EFFORTS IN INDIA